Risk Reduction
Conditions
Keywords
Typhoid
Brief summary
This is an open-label, non-randomized study. Volunteers will be vaccinated with the typhoid oral vaccine, Vivotif. Vivotif has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries. Volunteers will also be asked to provide blood, saliva, and stool specimens over a follow-up time period of up to eight years. The specimens obtained in this clinical research study will be used to further the investigator's understanding of the protective immunological mechanisms that can be elicited systemically and may be applicable to other enteric pathogens.
Interventions
The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
Sponsors
University of Maryland, Baltimore
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Volunteers who choose to take part in this study will receive the licensed FDA-approved Oral Typhoid Vaccine (Vivotif).
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 18 years and older * Good general health as determined by a screening evaluation within 28 days before blood donation * Informed, written consent
Exclusion criteria
* History of any of the following medical illnesses: * Diabetes * Cancer in past 5 years (except for basal cell carcinoma of the skin and cervical carcinoma in situ) * Heart disease (Hospitalization for a heart attack, coronary artery bypass graft, arrhythmia, or syncope, within past 5 years. Current symptoms of heart disease - dyspnea, angina, orthopnea) * Recurrent infections (more than 3 hospitalizations for invasive bacterial infections such as pneumonia or meningitis) * Current drug or alcohol abuse * Active ulcer disease or ongoing intestinal condition * Treatment for anemia in last 6 months * Currently being treated with anti-malarial drugs * Any of the following laboratory abnormalities detected during medical screening: * WBC \<0.81 x LLN or \> 1.09 x ULN * Hemoglobin \<0.91 x LLN or \>1.18 x ULN (women) or \<0.92 x LLN or \>1.18 x ULN (men) * Platelet count \<0.8 x LLN or \> 1.2 x ULN * (For leukopheresis or blood unit donations, the following lab values are exclusionary: * WBC \<3.5 or \>11 x 103/mm3; * Hemoglobin \<12.5 or \>18 g/dl * Platelet count \<150 or \>500 x 103/mm3) * SGOT or SGPT \>1.5 times normal * Positive serology for hepatitis C or HIV antibody or hepatitis B surface antigen * Positive serology for hepatitis B core antibody * Poor peripheral venous access for blood donation * Positive RPR * Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or interfere with the scientific integrity of study. * Positive urine pregnancy test (HCG) on day of vaccination. Prior to each blood donation -females with menstrual history consistent with pregnancy. Pregnant women will not be enrolled, because immunological changes that occur during pregnancy may interfere with laboratory assays.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Responders | approximately 5 years | Percentage of responders by cytokine production (Interferon-gamma (IFN-gamma) or Tumor Necrosis Factor-alpha (TNF-α)) by mass cytometry or flow cytometry. Responders will be defined as those volunteers showing increases post-immunization of \>0.1% of positive CD8+ cells for IFN-gamma or TNF-α over baseline (pre-immunization) values.) or Tumor Necrosis Factor-alpha (TNF-α)) by mass cytometry or flow cytometry. |
Countries
United States
Contacts
CONTACTSusan Holian, RN
Outcome results
None listed